Therapy options in Alzheimer's disease
- PMID: 7848798
Therapy options in Alzheimer's disease
Abstract
The aetiology of Alzheimer's disease and senile dementia of the Alzheimer type (AD/SDAT) are unknown, and primary prevention is thus infeasible. As overactivity in the hypothalamic-pituitary-adrenal axis (possibly indicating maladaptation to stress) and vitamin B12 deficiency are common, secondary prevention should focus on stress and dietary factors. Nerve growth factors and ganglioside GM1 have been used to inhibit progression of the disorder, but this treatment is still at an experimental stage, as are efforts to prevent the formation of amyloid. Breakthroughs in AD/SDAT treatment have been seen in trials with supplementation of neurotransmitter deficits. Tacrine, a drug that inhibits acetylcholinesterase, has proved to have a cognitive-enhancing effect, but this is limited in time and the drug has side-effects. Selective serotonin reuptake inhibitors have a proven effect on the emotional disturbances seen in AD/SDAT.
Similar articles
-
Pharmacological treatment of cognitive dysfunction in dementia disorders.Acta Neurol Scand Suppl. 1996;168:87-92. doi: 10.1111/j.1600-0404.1996.tb00379.x. Acta Neurol Scand Suppl. 1996. PMID: 8997426 Review.
-
Pharmacological treatment strategies in Alzheimer type dementia.Eur Neuropsychopharmacol. 1990 Nov;1(1):1-5. doi: 10.1016/0924-977x(90)90003-s. Eur Neuropsychopharmacol. 1990. PMID: 2136210 Review.
-
Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors.J Med Chem. 1997 Oct 24;40(22):3516-23. doi: 10.1021/jm970150t. J Med Chem. 1997. PMID: 9357518
-
Alzheimer's disease.Postgrad Med J. 1995 Apr;71(834):204-5. doi: 10.1136/pgmj.71.834.204. Postgrad Med J. 1995. PMID: 7784276 Free PMC article. No abstract available.
-
New cholinergic therapies: treatment tools for the psychiatrist.J Clin Psychiatry. 1998;59 Suppl 13:31-5. J Clin Psychiatry. 1998. PMID: 9771828 Review.
Cited by
-
Novel insights on GM1 and Parkinson's disease: A critical review.Glycoconj J. 2022 Feb;39(1):27-38. doi: 10.1007/s10719-021-10019-7. Epub 2022 Jan 22. Glycoconj J. 2022. PMID: 35064857 Free PMC article. Review.
-
GM1 Ganglioside Is A Key Factor in Maintaining the Mammalian Neuronal Functions Avoiding Neurodegeneration.Int J Mol Sci. 2020 Jan 29;21(3):868. doi: 10.3390/ijms21030868. Int J Mol Sci. 2020. PMID: 32013258 Free PMC article. Review.
-
Antibodies against gangliosides in patients with dementia.Am J Alzheimers Dis Other Demen. 2014 Dec;29(8):660-6. doi: 10.1177/1533317514534953. Epub 2014 May 16. Am J Alzheimers Dis Other Demen. 2014. PMID: 24838532 Free PMC article.
-
Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease--a review.J Lipid Res. 2008 Jun;49(6):1157-75. doi: 10.1194/jlr.R800007-JLR200. Epub 2008 Mar 11. J Lipid Res. 2008. PMID: 18334715 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials